#PTIX

5 days ago

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market Protagenic Therapeutics (OTCQB: PTIX) announced an upgrade from OTC Pink to OTCQB and commenced trading on OTCQB under the symbol PTIX on March 10, 2026. The move is intended to improve market visibility, trading liquidity and access to real-time quotes.The company said it completed a Phase 1 multiple-dose safety study showing a clean safety and tolerability profile and remains on track to begin Phase 2 enrollment in 2026 for lead candidate PT00114 targeting treatment-resistant depression and anxiety.

#PTIX Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

www.stocktitan.net/news/PTIX/protagenic-the...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Results from Phase 1 Multiple-Dose Study of PT00114 Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditionsNEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing therapeutics that target

#PTIX Results from Phase 1 Multiple-Dose Study of PT00114

www.stocktitan.net/news/PTIX/results-from-p...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study Protagenic Therapeutics (NASDAQ:PTIX) announced completion of enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study of lead peptide PT00114 in healthy volunteers on November 13, 2025. The trial evaluated safety and tolerability after multiple doses. The company said it will deliver a full summation of safety analysis by the end of the month and expects to release top-line MAD results by November 30, 2025. Protagenic noted it previously completed a single ascending dose study in early 2025 and described PT00114 as a first-in-class candidate targeting resilience to chronic stress and related neurological effects.

#PTIX Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study

www.stocktitan.net/news/PTIX/protagenic-the...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Biotech Protagenic Therapeutics Working to Maintain Nasdaq Compliance After Merger-Related Filing Delay Biotech firm Protagenic Therapeutics (PTIX) expects brief delay in Q2 2025 10-Q filing due to merger consolidation work. Nasdaq listing continues while company prepares compliance plan.

#PTIX Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance

www.stocktitan.net/news/PTIX/protagenic-the...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

6 months ago

Protagenic Therapeutics Moves PT00114 Forward, Eyes Key Catalysts in 2025–2026 Protagenic Therapeutics (NASDAQ: PTIX) has advanced its lead drug candidate PT00114 into the multiple-dose portion of its Phase 1 clinical trial, marking anothe

(NASDAQ: #PTIX)
#ProtagenicTherapeutics just advanced PT00114 into the multiple-dose Phase 1 trial—dosing complete by end of August & topline safety data expected September. Phase 2 could launch Q1 2026.
prismmarketview.com/protagenic-t...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders Protagenic Therapeutics (NASDAQ:PTIX) has announced significant progress in the clinical development of PT00114, its novel neuro-active peptide therapy. The company has completed first dose injection for all subjects in the multiple-dose portion of its Phase 1 trial, with full dosing completion expected by August end 2025.PT00114 is pioneering as the first investigational therapy based on Teneurin C-terminus Associated Peptide (TCAP), a natural brain hormone that regulates stress and emotional balance. The drug targets the amygdala and hippocampus, offering a differentiated approach to treating anxiety, depression, addiction, and PTSD.Following successful completion of a single ascending dose trial demonstrating favorable safety, the company anticipates topline safety data by September 2025 and plans to advance to Phase 2 efficacy studies in Q1 2026.

#PTIX Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

www.stocktitan.net/news/PTIX/protagenic-the...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Protagenic's Epilepsy Drug Patent Victory: Japan Grants 16-Year Exclusivity for Breakthrough Treatment New Japanese patent strengthens Protagenic's epilepsy drug pipeline with exclusive rights until 2041. Following UK approval, global expansion continues. Learn expansion plans.

#PTIX Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

www.stocktitan.net/news/PTIX/protagenic-the...

0 0 0 0

Feetr.io 🤖

@handle.invalid

9 months ago

🚀 Exciting times for #PTIX! Trading at $5.35, it's showing bullish momentum with a 10-day SMA of $4.86 and an 8-day EMA of $5.50. 📈 MACD is positive, but low volume hints at volatility. Consider entering at $5.40, targeting $6.00 & $6.50. Stop loss: $5.00. #FeetrAI

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Fresh $3.1M Funding Boosts Protagenic Therapeutics CNS Drug Pipeline After Major Merger New capital injection fuels advancement of stress disorder and CNS drug candidates following Phytanix Bio merger. See development timeline and pipeline expansion details.

#PTIX Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

www.stocktitan.net/news/PTIX/protagenic-the...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon May 19th - #RUN #SPCE #FUBO #LAES #WULF #BBAI #NVAX #PTIX #VLRS #RXRX #MVST #TLRY #SYTA #RR #QUBT #QBTS #KULR #HL #ASST - More: crystalequityresearch.com/SmCpStr/ - #smallcap

2 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

Breaking News: ( NASDAQ: #PTIX ) Today's Top Stocks include After Hours Movers

0 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

NEWS: ( NASDAQ: #PTIX ) Protagenic Therapeutics and Phytanix Bio to Merge, Creating Neuroactive Biopharmaceutical Powerhouse Targeting Obesity and CNS Disorders

0 0 0 0

Market Wire News

@marketwirenews.com

10 months ago

BREAKING NEWS: ( NASDAQ: #PTIX ) PTIX announced stock split 1-14

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split Protagenic Therapeutics has announced a 1-for-14 reverse stock split of its common stock, effective May 5, 2025. This strategic move aims to maintain Nasdaq compliance with minimum bid price requirements. The split will reduce outstanding shares from approximately 8.2 million to 588,750. Trading will continue under the symbol PTIX with a new CUSIP number (74365N301). Key points include: Stockholder approval received on April 18, 2025, for a ratio range of 1-for-10 to 1-for-20 Automatic conversion: 14 current shares will convert to 1 new share Fractional shares will be rounded up to the next whole share Proportionate adjustments will apply to exercise prices and equity awards Equiniti Trust Company, the transfer agent, will handle the conversion process. Book-entry holders require no action, while certificate holders will receive instructions via mail for share conversion.

#PTIX Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

www.stocktitan.net/news/PTIX/protagenic-the...

0 0 0 0